![The breaking news round-up: Decagear launches today, Pimax announces new headsets, and more! [APRIL FOOL’S]](https://i0.wp.com/skarredghost.com/wp-content/uploads/2025/03/lawk_glasses_handson.jpg?fit=1366%2C1025&ssl=1)
GSK to pay $1.2B upfront to snag Boston Pharma’s mid-stage MASH hope
GSK will hand over $1.2 billion in upfront cash to license a closely-watched candidate for fatty liver disease from Boston Pharmaceuticals. The drug in question is Boston’s lead asset, efimosfermin alfa. Previously known as BOS ...
GSK will hand over $1.2 billion in upfront cash to license a closely-watched candidate for fatty liver disease from Boston Pharmaceuticals.
The drug in question is Boston’s lead asset, efimosfermin alfa. Previously known as BOS ...
